Clinical Trials Browser

NIH × Neuroectodermal Tumors, Primitive, Peripheral × Irinotecan × Clear all

NCT01217437 2021-07-23

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Medulloblastoma, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

NCT00276692 2013-06-26

Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma

Phase 2 Completed

35 enrolled

Sarcoma

Sarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT00101270 2013-06-05

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

Phase 1 Completed

24 enrolled

CNSDermatologicGastrointestinalGenitourinaryHead & NeckLymphoidSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Colonic Neoplasms, Medulloblastoma, Melanoma, Nasopharyngeal Neoplasms, Wilms Tumor, Neuroblastoma, Recurrence, Osteosarcoma, Lymphoma, Large B-Cell, Diffuse, Neuroectodermal Tumors, Primitive, Peripheral, Optic Nerve Glioma, Dendritic Cell Sarcoma, Interdigitating